<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2004221964
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2020
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        KLACID 125MG-5ML SUSP
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        CLARITHROMYCIN
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        25
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg/ml
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Granules for suspension
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        60
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        1
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Bottle
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        NCE
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        24
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        do not store above 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        27.95
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="ABBVIE SRL" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            ABBVIE SRL
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 360]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Farouk, Maamoun Tamer & CO
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            Abbott Laboratories Limited
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        J01FA09
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Each 5ml spoonful of Klacid Granules for Oral Suspension 125mg/5ml contains 125 mg of the active ingredient clarithromycin.</p><p>Klacid belongs to a group of medicines called macrolide antibiotics. Antibiotics stop the growth of bacteria (bugs) that cause infections.</p><p>It is used to treat infections such as:</p><p>&bull; Upper respiratory tract infections for example, sinusitis, tonsillitis and pharyngitis.</p><p>&bull; Lower respiratory tract infections for example, acute and chronic bronchitis and pneumonia.</p><p>&bull; Skin and soft tissue infections of mild to moderate severity for example, impetigo, erysipelas, folliculitis, cellulitis, furunculosis, and infected wounds.<br />&bull; Treatment of acute otitis media</p><p>Klacid Granules for Oral Suspension 125mg/5ml is used in children 6 months to 12 years old.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; are&nbsp;<strong>allergic</strong>&nbsp;to clarithromycin, other macrolide antibiotics such as erythromycin or azithromycin, or any of the other ingredients of Klacid Granules for Oral Suspension 125mg/5ml.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; are taking medicines called ergot alkaloid (e.g. ergotamine or dihydroergotamine) or use ergotamine inhalers for migraine.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; are taking medicines called terfenadine or astemizole (widely taken for hay fever or allergies) or cisapride (for stomach disorders) or pimozide (for mental health problems) as combining these drugs can sometimes cause serious disturbances in heart rhythm. Consult your doctor for advice on alternative medicines.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; are taking other medicines which are known to cause serious disturbances in heart rhythm.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; are taking lovastatin or simvastatin (HMG-CoA reductase inhibitors, commonly known as statins, used to lower levels of cholesterol (a type of fat) in the blood).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; are taking oral midazolam (sedatives).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; have abnormally low levels of potassium in their blood (hypokalaemia).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; have&nbsp;<strong>severe</strong>&nbsp;liver disease with kidney disease.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; or someone in their family has a history of heart rhythm disorders (ventricular cardiac arrhythmia, including torsades de pointes) or abnormality of electrocardiogram (ECG, electrical recording of the heart) called &quot;long QT syndrome&quot;.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; are taking medicines called ticagrelor or ranolazine (for heart attack, chest pain or angina).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; are taking colchicine (usually taken for gout)</p><p><strong>Warning and precautions</strong></p><p>Talk to your doctor or pharmacist before giving Klacid Granules for Oral Suspension 125mg/5ml:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if your child has heart problems (e.g. heart disease, heart failure, an unusually slow heart rate or abnormally low levels of magnesium in the blood (hypomagnesaemia)).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if your child has any liver or kidney problems</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if your child has, or is prone to, fungal infections (e.g. thrush)</p><p><strong>Other medicines and Klacid Granules for Oral Suspension 125mg/5ml</strong></p><p>Tell your doctor if your child is taking any of the following medicines as their dose may need to be changed or they may need to have regular tests performed:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; digoxin, quinidine or disopyramide (for heart problems)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; warfarin, or any other anticoagulant (for blood thinning)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; carbamazepine, valproate, phenobarbital or phenytoin (for epilepsy)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; atorvastatin, rosuvastatin (HMG-CoA reductase inhibitors, commonly known as statins, and used to lower levels of cholesterol (a type of fat) in the blood). Statins can cause rhabdomyolysis (a condition which causes the breakdown of muscle tissue which can result in kidney damage) and signs of myopathy (muscle pain or muscle weakness) should be monitored.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; nateglinide, pioglitazone, repaglinide, rosiglitazone or insulin (used to lower blood glucose levels)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; gliclazide or glimepiride (sulphonylureas used in the treatment of type II diabetes)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; theophylline (used in patients with breathing difficulties such as asthma)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; triazolam, alprazolam or intravenous or oromucosal midazolam (sedatives)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; cilostazol (for poor circulation)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; methylprednisolone (a corticosteroid)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; vinblastine (for treatment of cancer)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ciclosporin, sirolimus and tacrolimus (immune suppressants)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; etravirine, efavirenz, nevirapine, ritonavir, zidovudine, atazanavir, saquinavir (anti-viral drugs used in the treatment of HIV)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; rifabutin, rifampicin, rifapentine, fluconazole, itraconazole (used in the treatment of certain bacterial infections)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; tolterodine (for overactive bladder)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; verapamil, amlodipine, diltiazem (for high blood pressure)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; sildenafil, vardenafil and tadalafil (for impotence in adult males or for use in pulmonary arterial hypertension (high blood pressure in the blood vessels of the lung))</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; St John&#39;s Wort (a herbal product used to treat depression)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; quetiapine or other antipsychotic medicines</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; other macrolide medicines</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; lincomycin and clindamycin (lincosamides - a type of antibiotic)</p><p>Please tell your doctor if your child suffers from diarrhea or vomiting while taking oral contraceptive pills, as she may need to take extra contraceptive precautions such as using a condom.</p><p><strong>Pregnancy and breast-feeding</strong></p><p>The safety of Klacid Granules for Oral Suspension 125mg/5ml in pregnancy and breast-feeding is not known. As Klacid Granules for Oral Suspension 125mg/5ml may be given to girls of child-bearing age you should speak to your doctor before giving this medicine if pregnancy is known or suspected.</p><p><strong>Driving and Using Machines:</strong></p><p>Klacid Granules for Oral Suspension may make you feel dizzy or drowsy. If they affect you or your child in this way do not drive, operate machinery or do anything that requires you to be alert.</p><p>Klacid Granules for Oral Suspension 125mg/5ml contains sucrose</p><p>This medicine contains sucrose , which is a type of sugar. If your child has been told that they have an intolerance to any sugars, contact your doctor before your child takes this medicine.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Always give Klacid Granules for Oral Suspension 125mg/5ml exactly as your doctor has told you. Check with your doctor or pharmacist if you are not sure how the dose has been worked out for your child.</p><p>The recommended doses of Klacid Granules for Oral Suspension 125mg/5ml are given below:</p><p><strong>Dosage based on body weight</strong></p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td><p>Weight (kg)</p></td><td><p>Age (years)</p></td><td><p>Dosage in mls (twice daily)</p></td></tr><tr><td><p>8-11</p></td><td><p>1-2</p></td><td><p>2.5</p></td></tr><tr><td><p>12-19</p></td><td><p>3-6</p></td><td><p>5</p></td></tr><tr><td><p>20-29</p></td><td><p>7-9</p></td><td><p>7.5</p></td></tr><tr><td><p>30-40</p></td><td><p>10-12</p></td><td><p>10</p></td></tr></tbody></table><p>&nbsp;</p><p>Children who weigh less than 8kg should be given a dose of 0.3 ml/kg twice a day. Doctors may sometimes prescribe higher or lower doses than these.</p><p>Klacid Granules for Oral Suspension 125mg/5ml should be given twice a day, once in the morning and again in the early evening. It can be given at mealtimes if this is more convenient.</p><p>You should shake the bottle well before using and close it tightly afterwards. Klacid Granules for Oral Suspension 125mg/5ml is usually given for 5 to 10 days.</p><p><strong>If you give more Klacid Granules for Oral Suspension 125mg/5ml than you should</strong></p><p>If you accidentally give your child more Klacid Granules for Oral Suspension 125mg/5ml in one day than your doctor has told you to, or if your child accidentally swallows some extra medicine, contact your doctor or nearest hospital emergency department immediately. An overdose of Klacid Granules for Oral Suspension 125mg/5ml is likely to cause vomiting and stomach pains.</p><p><strong>If you forget to give Klacid Granules for Oral Suspension 125mg/5ml</strong></p><p>If you forget to give your child a dose of medicine, give one as soon as you remember.</p><p>Do not give more Klacid Granules for Oral Suspension 125mg/5ml in one day than your doctor tells you to.</p><p><strong>If you stop giving Klacid Granules for Oral Suspension 125mg/5ml</strong></p><p>Do not stop giving this medicine even if your child feels better. It is important to give the medicine for as long as the doctor has told you to, otherwise the problem might come back.</p><p>If you have any further questions on the use of this medicine, ask your doctor or pharmacist.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, Klacid Granules for Oral Suspension 125mg/5ml can cause side effects although not everybody gets them.</p><p>If your child suffers from any of the following at any time during their treatment STOP giving the medicine and contact your doctor immediately:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; severe or prolonged diarrhoea, which may have blood or mucus in it. Diarrhoea may occur over two months after treatment with clarithromycin, in which case you should still contact your doctor.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; a rash, difficulty breathing, fainting or swelling of the face tongue, lips, eyes and throat. This is a sign that your child may have developed an allergic reaction.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; yellowing of the skin (jaundice), skin irritation, pale stools, dark urine, tender abdomen or loss of appetite. These are signs that your child&#39;s liver have inflammation and may not working properly.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; severe skin reactions such as painful blistering of the skin, mouth, lips, eyes and genitals (symptoms of a rare allergic reaction called Stevens-Johnson syndrome/toxic epidermal necrolysis).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; a red, scaly rash with bumps under the skin and blisters (symptoms of exanthematous pustulosis). The frequency of this side effect is not known (cannot be estimated from the available data).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; rare allergic skin reactions which cause severe illness with ulceration of the mouth, lips and skin which causes severe illness with rash, fever and inflammation of internal organs (DRESS).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; muscle pain or weakness known as rhabdomyolysis (a condition which causes the breakdown of muscle tissue which can result in kidney damage).</p><p>Other side effects</p><p>Common side effects (may affect up to 1 in 10 people) include:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; difficulty sleeping</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; changes in sense of taste</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; headache</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; widening of blood vessels</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; stomach problems such as feeling sick, vomiting, stomach pain, indigestion, diarrhoea</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; increased sweating</p><p>Uncommon side effects (may affect up to 1 in 100 people) include:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; high temperature</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; swelling, redness or itchiness of the skin</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; oral or vaginal &#39;thrush&#39; (a fungal infection)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; inflammation of the stomach and intestines</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; decrease of the levels of blood platelets (blood platelets help stop bleeding)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; decrease in white blood cells (leukopenia)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; decrease in neutrophils (neutropenia)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; stiffness</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; chills</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; increase of eosinophils (white blood cells involved in immunity)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; exaggerated immune response to a foreign agent</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; lack or loss of appetite</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; anxiety, nervousness</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; drowsiness, tiredness, dizziness or shaking</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; involuntary muscle movements</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; vertigo</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ringing in the ears or hearing loss</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; chest pain or changes in heart rhythm such as palpitations or an irregular heartbeat</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; asthma: lung disease associated with tightening of air passages, making breathing difficult</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; nose bleed</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; blood clot that causes sudden blockage in a lung artery (pulmonary embolism)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; inflammation of the lining of the gullet (oesophagus) and lining of the stomach</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; anal pain</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; bloating, constipation, wind, burping</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; dry mouth</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; situation where the bile (fluid made by the liver and stored in the gallbladder) cannot flow from the gallbladder to the duodenum (cholestasis)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; inflammation of the skin characterized by the presence of the bullae which are filled with fluid, itchy and painful rash</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; muscle spasms, muscle pain or loss of muscle tissue. If your child suffers from myasthenia gravis (a condition in which the muscles become weak and tire easily), clarithromycin may worsen these symptoms</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; raise of abnormal kidney and liver function blood test and raised blood tests</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; feeling weak, tired and having no energy</p><p>Not known side effects (frequency cannot be estimated from the available data):</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; inflammation of the colon</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; bacterial infection of the outer layers of the skin</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; reduction in the &nbsp;number of certain blood cells (which can make infections more likely or increase the risk of bruising or bleeding)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; confusion, loss of bearings, hallucinations (seeing things), change in sense of reality or panicking, depression, abnormal dreams or nightmares and mania (feeling of elation or over-excitement)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; convulsion (fits)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; paraesthesia, more commonly known as &#39;pins and needles&#39;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; loss of taste or smell or inability to smell properly</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; type of heart rhythm disorder (Torsade de pointes, ventricular tachycardia)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; loss of blood (haemorrhage)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; inflammation of the pancreas</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; discolouration of the tongue or teeth</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; acne</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; change in the levels of products produced by the kidney, inflammation of the kidney or an inability of the kidney to function properly (you may notice tiredness, swelling or puffiness in the face, abdomen, thighs or ankles or problems with urination)</p><p>If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet.&nbsp;By reporting side effects you can help provide more information on the safety of this medicine</p><p><strong>To report any side effect(s):</strong></p><p>-National Pharmacovigilance Center (NPC)</p><p><strong>o </strong>Fax: +966-11-205-7662</p><p><strong>o </strong>SFDA Call Center: 19999</p><p>o E-mail: npc.drug@sfda.gov.sa</p><p>o Website: https://ade.sfda.gov.sa</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Keep this medicine out of sight and reach of children</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Shelf life: 24 months</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Do not use this medicine after its use-by (exp.) date that is printed on the label.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Store at temperature below 30&deg;C</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; After reconstitution, you can store at temperature up to 30&deg;C for 14 days</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>What Klacid Granules for Oral Suspension 125mg/5ml contains</strong></p><p>Each 5ml spoonful of Klacid Granules for Oral Suspension 125mg/5ml contains 125 mg of the active ingredient clarithromycin.</p><p>Other ingredients are: sucrose, carbopol carbomers, povidone, hypromellose, castor oil, silicon dioxide, xanthan gum, fruit punch flavour, potassium sorbate, citric acid, maltodextrin and titanium dioxide..</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                What Klacid Granules for Oral Suspension 125mg/5ml looks like and contents of the pack

Klacid Granules for Oral Suspension 125mg/5ml is an off-white colour and is available in bottles of 60ml and 100 ml.

It is provided with a measuring spoon. Not all pack sizes may be marketed
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Marketing Authorisation Holder:</strong></p><p>Abbott Laboratories Ltd.</p><p>Abbott House, Vanwall Business park</p><p>Vanwall Road, Maidenhead Berkshire</p><p>SL6 4XE, UK</p><p><strong>Manufacturer:</strong></p><p>AbbVie S.R.L</p><p>Campoverde di Aprilia (LT), Italy.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                June 2020
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL">تحتوي كل ملعقة سعة 5 ملليلتر من كلاسيد حبيبات لمعلق عن طريق الفم 125 ملغم/ 5 مل على 125 ملغم من المادة الفعالة كلاريثرومايسين.</p><p dir="RTL">كلاسيد ينتمي إلى مجموعة من الأدوية تسمى المضادات الحيوية الماكروليدية. المضادات الحيوية تعمل على وقف نمو البكتيريا (الميكروبات) التي تسبب العدوى.</p><p dir="RTL"><strong>وهو يستخدم لعلاج العدوى مثل:</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عدوى الجهاز التنفسي العلوي مثل التهاب الجيوب الأنفية، التهاب اللوزتين، والتهاب البلعوم.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عدوى الجهاز التنفسي السفلي مثل التهاب الشعب الحاد أو المزمن والتهاب الرئة.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; العدوى الخفيفة أو متوسطة الخطورة في الجلد والأنسجة الرخوة، مثل الحصف، والحمرة، والتهاب الأجربة، والتهاب النسيج الخلوي الرخو تحت الجلد، والدمامل، والجروح المتقيحة.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب الأذن الوسطى الحاد.</p><p dir="RTL">كلاسيد حبيبات لمعلق عن طريق الفم 125 ملغم/ 5 مل يستخدم للأطفال من سن 6 أشهر إلى 12 سنة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لديه <strong>حساسية</strong> من كلاريثرومايسين، والمضادات الحيوية الأخرى التي تنتمي إلى مجموعة ماكروليد مثل اريثروميسين أو أزيثروميسين، أو من أي من المكونات الأخرى في كلاسيد حبيبات لمعلق عن طريق الفم 125 ملغم/ 5 مل.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يتناول أدوية تسمى قلويدات الأرجوت (مثل الإرجوتامين أو دايهيدروإرجوتامين) أو بخاخات الإرجوتامين &nbsp;بالاستنشاق لعلاج الصداع النصفي.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يتناول أدوية تسمى ترفينادين أو أستيميزول (تؤخذ على نطاق واسع لحمى الكلأ أو الحساسية) أو سيسابريد (لاضطرابات المعدة) أو بيموزيد (لمشاكل الصحة النفسية) حيث إن تناول هذه الأدوية معاً يمكن أن يسبب أحياناً اضطرابات خطيرة في &nbsp;نظم القلب. استشر طبيبك بشأن تناول الأدوية البديلة.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يتناول أدوية أخرى من المعروف أنها تسبب اضطرابات خطيرة في &nbsp;نظم القلب.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يتناول لوفاستاتين أو سيمفاستاتين (مثبطات مختزلة HMG-CoA المعروفة باسم الستاتينات، والتي تُستخدم لخفض مستويات الكولسترول (نوع من الدهون) في الدم).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يتناول ميدازولام عن طريق الفم (مهدئ).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يعاني من انخفاض مستويات البوتاسيوم في الدم بشكل غير طبيعي (نقص بوتاسيوم الدم).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مصاباً بأمراض كبدية <strong>شديدة</strong> مع أمراض الكلى.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; شخصاً ما في عائلته لديه تاريخ من اضطرابات ضربات القلب (عدم انتظام ضربات القلب البطيني، بما في ذلك حالة تورساد دي بوانت) أو شذوذ مخطط كهربائية القلب (خلل في رسم القلب والتسجيل الكهربائي للقلب) يسمى &quot;متلازمة&nbsp;كيو تي الطويلة &quot;.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يتناول أدوية تسمى تيكاجريلور أو رانولازين (للنوبة القلبية أو لألم الصدر أو الذبحة الصدرية).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يتناول الكولشيسين (عادة ما يؤخذ للنقرس)</p><p dir="RTL"><strong>التحذيرات والاحتياطات:</strong></p><p dir="RTL"><strong>تحدث مع طبيبك أو الصيدلي قبل تناول كلاسيد حبيبات لمعلق عن طريق الفم 125 ملغم/ 5 مل في الحالات التالية:</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كان طفلك يعاني من مشاكل في القلب (مثل أمراض القلب أو قصور القلب أو بطء في معدل ضربات القلب بشكل غير عادي أو الانخفاض غير الطبيعي لمستويات المغنيسيوم في الدم (نقص مغنيسيوم الدم)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كان طفلك لديه أي مشاكل في الكبد أو الكلى</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كان طفلك لديه حاليًا، أو كان عرضة للعدوى الفطرية (على سبيل المثال القلاع)</p><p dir="RTL"><strong>تناول أدوية اخرى مع كلاسيد، حبيبات لمعلق عن طريق الفم 125 ملغم/ 5 مل:</strong></p><p dir="RTL">أخبر طبيبك إذا كان طفلك يتناول أيّاً من الأدوية التالية، حيث قد تكون هناك حاجة إلى تغيير جرعتهم أو إجراء بعض الفحوصات لهم بانتظام:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ديجوكسين أو كويندين أو ديزوبراميد (لعلاج مشكلات القلب).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; وارفارين، أو أي من مضادات التجلط الأخرى (لإسالة الدم)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كاربامازيبين، ڤالبروات، فينوباربيتال أو فيناتون (أدوية الصرع).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أتورفاستاتين، روسوفاستاتين (مثبطات مختزلة HMG-CoA المعروفة على نحو شائع باسم الستاتينات، والتي تُستخدم لخفض مستويات الكولسترول (نوع من الدهون) في الدم). الستاتينات يمكنها أن تسبب انحلال العضلات المخططـة الهيكليـة (الحالة التي يحدث فيها انهيار الأنسجة العضلية والتي يمكن أن تؤدي إلى تلف الكلى) ومن ثم ينبغي مراقبة أعراض الاعتلال العضلي (آلام العضلات أو ضعف العضلات).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ناتيجلينيدين، بيوجليتازون، ريباجلينيد، روزيجليتازون أو الأنسولين (التي تستخدم لخفض مستويات الجلوكوز في الدم)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; جليكلازيد أو جليميبيريد (أدوية السلفونيل يوريا المستخدمة في علاج النوع الثاني من مرض السكري)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ثيوفيللين (يُستخدم في علاج المرضى المصابين بصعوبات تنفسية مثل الربو).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ترايازولام، البرازولام، ميدازولام المستخدم عبر للغشاءالغشاء المخاطي الفموي أو عن طريق الوريد (مهدئ).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سيلوستازول (لعلاج قصور الدورة الدموية).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ميثيل بردنيزولون (كورتيكوستيرويد).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ڤينبلاستين (لعلاج السرطان).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سيكلوسبورين، سيروليميس، تاكروليميس (مثبطات المناعة).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إترافيرين، إيفافيرنز، نيفيرابين، ريتونافير، زيدوفودين، أتازانافير، ساكينافير (الأدوية المضادة للفيروسات المستخدمة في علاج فيروس نقص المناعة البشرية)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ريفابيوتين، ريفامبيسين، ريفابنتين، فلوكانازول، أيتراكونازول (تُستخدم في علاج بعض الالتهابات البكتيرية).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تولتيرودين (لعلاج فرط نشاط المثانة).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فيراباميل، أملوديبين، ديلتيازيم (لارتفاع ضغط الدم).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سيلدينافيل، فاردينافيل، تادالافيل (لعلاج العجز الجنسي عند الذكور البالغين أو للاستخدام في علاج ارتفاع ضغط الدم الشرياني الرئوي (ارتفاع ضغط الدم في الأوعية الدموية في الرئة)).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عشبة سانت جون (منتج عشبي يُستخدم لعلاج الاكتئاب).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كيتيابين أو الأدوية الأخرى المضادة للذهان.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الأدوية الماكروليدية الأخرى</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لينكوميسين وكليندامايسين (لينكوساميدات - نوع من المضادات الحيوية)</p><p dir="RTL">يرجى إبلاغ طبيبك إن كانت ابنتك تتناول حبوب منع الحمل &nbsp;وتعرّضت لإسهال أو قيء، لأنها قد تحتاج لاحتياطات إضافية لمنع الحمل مثل استخدام واقٍ ذكري عند ممارسة العلاقة الحميمية.</p><p dir="RTL"><strong>الحمل والرضاعة الطبيعية:</strong></p><p>إن سلامة استخدام كلاسيد، حبيبات لمعلق عن طريق الفم 125 ملغم /5 مل في الحمل والرضاعة غير معروفة. وحيث إنه قد يُعطى للفتيات في سن الإنجاب، فيجب عليك التحدث إلى الطبيب قبل إعطاء هذا الدواء لابنتك في حالة التيقن من الحمل أو الاشتباه في حدوثه.</p><p dir="RTL"><strong>القيادة واستخدام الآلات:</strong></p><p>كلاسيد، حبيبات لمعلق عن طريق الفم 125 &nbsp;ملغم/ 5 مل قد يجعلك تشعر بالدوار أو النعاس. إذا كان هذا الدواء يؤثر على طفلك بهذه الطريقة، فيجب عدم القيادة أو تشغيل الآلات أو القيام بعمل يتطلب منك أن تكون في حالة يقظة.</p><p dir="RTL">يحتوي كلاسيد، حبيبات لمعلق عن طريق الفم 125 &nbsp;ملغم/ 5 مل على سكروز</p><p>يحتوي هذا الدواء على سكروز، وهو نوع من السكر. إذا أخبرك الأطباء أن طفلك لا يتحمل أيّاً من السكريات، فتواصل مع طبيبك قبل أن يتناول طفلك هذا الدواء.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>يجب تناول جرعة كلاسيد، حبيبات لمعلق عن طريق الفم 125 &nbsp;ملغم/ 5 مل كما يصفها الطبيب. يجب عليك أن تستشير طبيبك أو الصيدلي إذا كنت غير متأكد من الجرعة المقررة لطفلك.</p><p>تُعطى الجرعة الموصى بها من كلاسيد، حبيبات لمعلق عن طريق الفم 125 &nbsp;ملغم/ 5 مل كما يلي:</p><p><strong>الجرعة بناءً على وزن الجسم</strong></p><table dir="rtl" border="0" cellspacing="0" cellpadding="0"><tbody><tr><td><p dir="RTL">وزن الطفل (كجم)</p></td><td><p dir="RTL">عمر الطفل (سنة)</p></td><td><p dir="RTL">الجرعة بوحدة مل (مرتين يومياً)</p></td></tr><tr><td><p dir="RTL">8-11</p></td><td><p dir="RTL">1-2</p></td><td><p dir="RTL">2.5</p></td></tr><tr><td><p dir="RTL">12-19</p></td><td><p dir="RTL">3-6</p></td><td><p dir="RTL">5</p></td></tr><tr><td><p dir="RTL">20-29</p></td><td><p dir="RTL">7-9</p></td><td><p dir="RTL">7.5</p></td></tr><tr><td><p dir="RTL">30-40</p></td><td><p dir="RTL">10-12</p></td><td><p dir="RTL">10</p></td></tr></tbody></table><p>وينبغي إعطاء الأطفال الذين يزنون أقل من 8 كجم جرعة من 0.3 مل/ كجم مرتين في اليوم. قد يصف الأطباء أحياناً جرعات أعلى أو أقل من تلك الجرعات.</p><p>ينبغي إعطاء كلاسيد، حبيبات لمعلق عن طريق الفم 125 &nbsp;ملغم/ 5 مل مرتين في اليوم، جرعة في الصباح وجرعة في المساء، ويمكن إعطاؤه في وقت الوجبات إذا كان ذلك أسهل لك.</p><p>يجب رج الزجاجة جيداً قبل الاستخدام وإغلاقها بإحكام بعد الاستخدام، وعادة ما تستمر فترة إعطاء كلاسيد، حبيبات لمعلق عن طريق الفم 125 &nbsp;ملغم/ 5 مل من 5 إلى 10 أيام</p><p dir="RTL"><strong>إذا أعطيت طفلك جرعة زائدة من كلاسيد، حبيبات لمعلق عن طريق الفم 125 &nbsp;ملغم/ 5 مل</strong></p><p>إذا أعطيت طفلك بطريق الخطأ جرعة زائدة من كلاسيد، حبيبات لمعلق عن طريق الفم 125 &nbsp;ملغم/ 5 مل عن تلك الجرعة التي أخبرك الطبيب بإعطائها له، أو إذا ابتلع طفلك بطريق الخطأ جرعة زائدة فى يوم واحد، فاتصل بالطبيب أو بأقرب مستشفى أو قسم طوارئ عَلى الفور حيث إن الجرعة الزائدة تسبب التقيؤ وآلام في المعدة.</p><p dir="RTL"><strong>إذا نسيت أن &nbsp;تعطي طفلك كلاسيد، حبيبات لمعلق عن طريق الفم 125 &nbsp;ملغم/ 5 مل</strong></p><p>إذا نسيت أن تعطي طفلك جرعة من الدواء، فيمكن إعطاؤه تلك الجرعة في أقرب وقت تتذكرها. لا تعطِ أكثر من الجرعة التي وصفها لك الطبيب في يوم واحد.</p><p dir="RTL"><strong>&nbsp;التوقف عن إعطاء كلاسيد، حبيبات لمعلق عن طريق الفم 125 &nbsp;ملغم/ 5 مل</strong></p><p>لا توقف إعطاء كلاسيد، حبيبات لمعلق عن طريق الفم 125 &nbsp;ملغم/ 5 مل حتى لو كان يشعر طفلك بتحسن ومن المهم أن تعطيه الدواء للمدة التي حددها لك الطبيب، وإلا فإن المرض قد يعود مرة أخرى.إذا كان لديك أي أسئلة أخرى حول استخدام هذا الدواء، فاسأل طبيبك أو الصيدلي.</p><p>&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p>مثل جميع الأدوية، يمكن أن يسبب كلاسيد، حبيبات لمعلق عن طريق الفم 125 &nbsp;ملغم/ 5 مل بعض الآثار الجانبية على الرغم من عدم حدوث ذلك لكل الأشخاص.</p><p>إذا كان طفلك يعاني من أي من الأعراض التالية في أي وقت أثناء العلاج، فيجب إيقاف الدواء والاتصال بالطبيب على الفور:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الإسهال الشديد أو الإسهال لفترات طويلة، والذي قد يكون مختلطاً بدم أو بمخاط. قد يحدث الإسهال على مدى أكثر من شهرين بعد العلاج بالكلاريثرومايسين وإذا حدث ذلك، يجب الاتصال بالطبيب.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; طفح جلدي، أو صعوبة التنفس، أو الإغماء، أو تورم الوجه أو اللسان أو الشفتين أو العينين أو الحلق. وهذه علامة على احتمال إصابة طفلك برد فعل تحسسي.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اصفرار الجلد (اليرقان)، أو تهيج الجلد، أو البراز فاتح اللون، أو البول غامق اللون، أو إيلام البطن عند لمسها، أو فقدان الشهية. وتلك علامات على أن كبد طفلك مصاب بالالتهاب وأنه قد لا يؤدي وظيفته بشكل سليم.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تفاعلات جلدية شديدة مثل تقرحات مؤلمة في الجلد والفم والعينين والشفتين والأعضاء التناسلية، (أعراض لتفاعل حساسية نادر يسمى متلازمة ستيفنز جونسون/ تقشر الأنسجة المتموتة البشروية التسممي).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; طفح جلدي أحمر ومتقشر، مع تحاديب تحت الجلد وبثور (أعراض البثار الطفحي). معدّل تكرار هذا الأثر الجانبي مجهول (أي لا يمكن تقديره من خلال البيانات المتاحة).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تفاعلات حساسية نادرة بالجلد تسبب مرضاً شديداً مصحوباً بتقرّح الفم والشفتين والجلد، مما يسبب مرضاً شديداً يصاحبه طفح جلدي وحمى والتهاب الأعضاء الداخلية (متلازمة DRESS).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم أو ضعف في العضلات يُعرف باسم انحلال الربيدات (وهي حالة تتسبب في انهيار الأنسجة العضلية والتي يمكن أن تؤدي إلى تلف الكلى).</p><p dir="RTL">آثار جانبية أخرى</p><p dir="RTL">الآثار الجانبية الشائعة (قد تؤثر على ما يصل إلى 1 من أصل 10 أشخاص) وتشمل:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; صعوبة النوم</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التغيرات في حاسة التذوق</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الصداع</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اتساع الأوعية الدموية</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مشاكل في المعدة مثل الشعور بالإعياء، والتقيؤ، وآلام في المعدة، وعسر الهضم، والإسهال</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; زيادة التعرق</p><p dir="RTL">الآثار الجانبية غير الشائعة (قد تؤثر على ما يصل إلى 1 من أصل 100 شخص) وتشمل:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ارتفاع درجة الحرارة</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تورم، احمرار أو حكة في الجلد</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عدوى فطرية بالفم أو المهبل (القلاع)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب المعدة والأمعاء</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض مستويات الصفائح الدموية (الصفائح الدموية تساعد على وقف النزيف)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض في عدد خلايا الدم البيضاء (نقص الكريات البيض)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض في تعداد الكريات البيض المعتدلة (نقص العدلات)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التصلب</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; القشعريرة</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; زيادة الحمضات (ارتفاع مستوى الكريات البيضاء الحمِضة المساعدة في المناعة)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; زيادة الاستجابة المناعية للأجسام الغريبة.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نقص الشهية أو فقدانها</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; القلق والعصبية</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نعاس، تعب، دوخة أو رعشة</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حركات لا إرادية بالعضلات</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الدوار</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; رنين في الأذنين أو فقدان السمع</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم في الصدر أو تغيرات في إيقاع نبض القلب مثل الخفقان أو عدم انتظام ضربات القلب</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الربو: أمراض الرئة المرتبطة بتضيق الممرات الهوائية، مما يجعل التنفس صعباً</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نزيف الأنف</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تجلط الدم الذي يسبب انسداداً مفاجئاً في شريان الرئة (الانصمام الرئوي)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب بطانة المريء وبطانة المعدة</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم بالشرج</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الانتفاخ والإمساك وخروج الغازات من البطن والتجشؤ</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; جفاف الفم</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ركود الصفراء (السوائل التي يفرزها الكبد وتخزن في المرارة) وفي هذه الحالة لا يمكن أن تتدفق الصفراء من المرارة إلى الاثني عشر (الركود الصفراوي)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب الجلد الذي يتميز بوجود فقاعات مليئة بالسوائل، وبالطفح الجلدي المؤلم والمثير للحكة</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تشنجات العضلات، آلام في العضلات أو فقدان الأنسجة العضلية. إذا كان طفلك يعاني من الوهن العضلي الوبيل (وهي حالة تصبح فيها العضلات ضعيفة ويصيبها التعب بسهولة)، فقد يؤدي كلاريثرومايسين إلى تفاقم هذه الأعراض</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نتائج مرتفعة وغير طبيعية لاختبارات الدم لوظائف الكلى والكبد وغيرها من اختبارات الدم</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الشعور بالضعف والتعب وفقدان الطاقة</p><p dir="RTL">الآثار الجانبية غير المعروفة (لا يمكن تقدير معدل تكرارها من البيانات المتاحة):</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب القولون</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عدوى بكتيرية في الطبقات الخارجية من الجلد</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض مستوى بعض خلايا الدم (التي يمكن أن تزيد من احتمالية الإصابة بالعدوى أو تزيد من خطر الكدمات أو النزيف)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الارتباك، وفقدان إدراك الاتجاهات، والهلوسة (رؤية أشياء غير حقيقية)، وتغير الشعور بالواقع أو الفزع، والاكتئاب، والأحلام غير الطبيعية أو الكوابيس والهوس (الشعور &nbsp;بالابتهاج والانتشاء أو فرط الاستثارة)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التشنج (نوبات)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التنميل، وغالباً ما يتم الشعور به على هيئة إحساس بوخذ الدبابيس والإبر</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فقدان حاسة التذوق أو الشم أو عدم القدرة على الشم بشكل صحيح</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نوع من اضطراب ضربات القلب (تورساد دي بوانت، تسرع&nbsp;القلب&nbsp;البطيني)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فقدان الدم (النزف)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب البنكرياس</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تغير لون اللسان أو الأسنان</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حب الشباب</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تغير في مستويات إفرازات الكلى، التهاب الكلى أو عدم قدرة الكلى على العمل بشكل صحيح (قد تلاحظ التعب، التورم أو الانتفاخ في الوجه والبطن والفخذين أو الكاحلين أو مشكلات في التبول)</p><p dir="RTL">إذا أُصبت بأي &nbsp;أعراض جانبية، فأبلغ الطبيب المعالج أو الصيدلي. وهذا يشمل أي آثار جانبية محتملة غير مدرجة في هذه النشرة. بالإبلاغ عن الآثار الجانبية، يمكنك المساعدة في توفير مزيد من المعلومات حول أمان هذا الدواء.</p><p dir="RTL"><strong>للإبلاغ عن الأعراض الجانبية</strong></p><p dir="RTL"><strong>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>المركز الوطني للتيقظ والسلامة الدوائية (</strong><strong>NPC</strong><strong>)</strong></p><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp; فاكس 7662-205-11-966+</p><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp; مركز الاتصال: 19999</p><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp; البريد الإلكتروني: npc.drug@sfda.gov.sa</p><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp; الموقع الإلكتروني: https://ade.sfda.gov.sa</p><p dir="RTL">&nbsp;</p><p>&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>&middot;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>يحفظ بعيداً عن متناول أيدي الأطفال ومرآهم.</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; فترة الصلاحية: 24 شهراً</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; لا تستخدم هذا الدواء بعد تاريخ انتهاء الصلاحية المطبوع على الشريط والعلبة الخارجية.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; يحفظ في درجة حرارة أقل من 30 درجة مئوية.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; بعد التحضير، يمكن الحفظ في درجة حرارة 30 درجة مئوية لمدة 14 يوم</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; لا ينبغي أن يتم التخلص من الأدوية في مياه الصرف الصحي أو عن طريق النفايات المنزلية. اسأل الصيدلي عن كيفية التخلص من الأدوية التي لم تعد مطلوبة. هذه التدابير تساعد في الحفاظ على البيئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>محتوى عبوة كلاسيد، حبيبات لمعلق عن طريق الفم 125 &nbsp;ملغم/ 5 مل</strong></p><p dir="RTL">تحتوي كل معلقة سعة 5 مل من كلاسيد، حبيبات لمعلق عن طريق الفم 125 &nbsp;ملغم/ 5 مل على المادة الفعالة كلاريثرومايسين بتركيز 125 ملغم.</p><p dir="RTL">المكونات الأخرى هي: سكروز، كاربومير الكاربوبول، بوفيدون، هيبروميلوز، زيت الخروع، ثاني أكسيد السيليكون، صمغ الزنتان، نكهة الفواكه، سوربات البوتاسيوم، حامض الستريك، مالتوديكسترين وثاني أكسيد التيتانيوم.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>&nbsp;الشكل الصيدلاني لكلاسيد، حبيبات لمعلق عن طريق الفم 125 &nbsp;ملغم/ 5 مل ومحتويات العلبة؟</strong></p><p dir="RTL">كلاسيد، حبيبات لمعلق عن طريق الفم 125 &nbsp;ملغم/ 5 مل عبارة عن مسحوق ذي لون أبيض قاتم معبأ في زجاجة سعة 60 مل أو 100 مل.</p><p dir="RTL">يتم توفيرها مع ملعقة مُدرَّجة. قد لا تتوفر كافة العبوات في السوق.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>صاحب حق التسويق:</strong></p><p dir="RTL">أبوب لابوراتوريز ليميتد،</p><p dir="RTL">أبوت هاوس، فانوال بزنس بارك،</p><p dir="RTL">فانوال رود، ميدينهيد بيركشر، إس إل 6 4 إكس إي، المملكة المتحدة</p><p dir="RTL"><strong>الشركة المصنعة:</strong></p><p dir="RTL">أبفي إس. أر. إل، كامبوفيردي دي أبريليا، إيطاليا.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            يونيو 2020
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Klacid® Granules for Oral Suspension 125mg/5ml
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Each 5 ml of the granules for suspension contains 125 mg of clarithromycin.
Excipient with known effect:
sucrose 550 mg/ml
castor oil, virgin 3.2mg/ml
For a full list of excipients, see section 6.1.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                White to off - white granules for reconstitution.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Klacid Granules for Oral Suspension 125mg/5ml is indicated in children 6 months<br />to 12 years.<br />Klacid Granules for Oral Suspension 125mg/5ml is indicated for the treatment of<br />infections caused by susceptible organisms. Indications include:<br />- Lower respiratory tract infections (e.g. bronchitis, pneumonia) (see section 4.4<br />and 5.1 regarding Sensitivity Testing).<br />- Upper respiratory tract infections (e.g. pharyngitis, sinusitis).<br />- Skin and soft tissue infections (e.g. folliculitis, cellulitis, erysipelas) (see<br />section 4.4 and 5.1 regarding Sensitivity Testing).<br />- Acute otitis media.<br />Consideration should be given to official guidance on the appropriate use of<br />antibacterial agents.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Paediatric patients under 12 years of age<br />Clinical trials have been conducted using Klacid Granules for Oral Suspension in<br />children 6 months to 12 years of age. Therefore, children under 12 years of age<br />should use Klacid Granules for Oral Suspension.<br />Recommended doses and dosage schedules:<br />The usual duration of treatment is for 5 to 10 days depending on the pathogen<br />involved and the severity of the condition. The recommended daily dosage of<br />Klacid Granules for Oral Suspension 125mg/5ml in children is given in the<br />following table and is based on a 7.5mg/kg b.i.d. dosing regime up to a maximum<br />dose of 500 mg b.i.d. The prepared suspension can be taken with or without meals<br />and can be taken with milk.<br />KLACID GRANULES FOR ORAL SUSPENSION 125mg/5ml DOSAGE IN CHILDREN</p><p>&nbsp;</p><table border="1" cellspacing="1" cellpadding="1" style="width:500px"><tbody><tr><td colspan="3" style="text-align:center">Dosage Based on Body Weight (kg)</td></tr><tr><td style="text-align:center">Weight*<br />(kg)</td><td style="text-align:center">Approx Age<br />(yrs)</td><td style="text-align:center">Dosage<br />(ml)<br />bid</td></tr><tr><td style="text-align:center">8-11</td><td style="text-align:center">1 -2</td><td style="text-align:center">2.50</td></tr><tr><td style="text-align:center">12-19</td><td style="text-align:center">3 - 6</td><td style="text-align:center">5.00</td></tr><tr><td style="text-align:center">20-29</td><td style="text-align:center">7 - 9</td><td style="text-align:center">7.50</td></tr><tr><td style="text-align:center">30-40</td><td style="text-align:center">10 - 12</td><td style="text-align:center">10.00</td></tr></tbody></table><p>* Children &lt; 8 kg should be dosed on a per kg basis (approx. 7.5 mg/kg bid)</p><p>Renal Impairment<br />In children with creatinine clearance less than 30 ml/min/1.73m2, the dosage of<br />clarithromycin should be reduced by half to 7.5mg/kg per day.<br />Dosage should not be continued beyond 14 days in these patients.<br />Preparation for use: see section 6.6</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hypersensitivity to macrolide antibiotic drugs or to any of the excipients listed in
section 6.1.
Concomitant administration of clarithromycin and ergot alkaloids (e.g. ergotamine
or dihydroergotamine) is contraindicated, as this may result in ergot toxicity (see
section 4.5).
Concomitant administration of clarithromycin and oral midazolam is
contraindicated (see section 4.5).
Concomitant administration of clarithromycin and any of the following drugs is
contraindicated: astemizole, cisapride, pimozide and terfenadine as this may
result in QT prolongation and cardiac arrhythmias, including ventricular
tachycardia, ventricular fibrillation, and torsades de pointes (see section 4.5).
Clarithromycin should not be given to patients with history of QT prolongation
(congenital or documented acquired QT prolongation) or ventricular cardiac
arrhythmia, including torsades de pointes (see sections 4.4 and 4.5).
Concomitant administration with ticagrelor or ranolazine is contraindicated.
Clarithromycin should not be used concomitantly with HMG-CoA reductase
inhibitors (statins) that are extensively metabolized by CYP3A4, (lovastatin or
simvastatin), due to the increased risk of myopathy, including rhabdomyolysis
(see section 4.5).
As with other strong CYP3A4 inhibitors, Clarithromycin should not be used in
patients taking colchicine (see sections 4.4 and 4.5).
Clarithromycin should not be given to patients with hypokalaemia (risk of
prolongation of QT-time).
Clarithromycin should not be used in patients who suffer from severe hepatic
failure in combination with renal impairment.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The physician should not prescribe clarithromycin to pregnant women without<br />carefully weighing the benefits against risk, particularly during the first three<br />months of pregnancy (see section 4.6).<br />Clarithromycin is principally metabolised by the liver. Therefore, caution should<br />be exercised in administering this antibiotic to patients with impaired hepatic<br />function.<br />Caution should also be exercised when administering clarithromycin to patients<br />with moderate to severe renal impairment (see section 4.2).<br />Hepatic dysfunction, including increased liver enzymes, and hepatocellular and/or<br />cholestatic hepatitis, with or without jaundice, has been reported with<br />clarithromycin. This hepatic dysfunction may be severe and is usually reversible.<br />Cases of fatal hepatic failure (see section 4.8) have been reported. Some patients<br />may have had pre-existing hepatic disease or may have been taking other<br />hepatotoxic medicinal products. Patients should be advised to stop treatment and</p><p>contact their doctor if signs and symptoms of hepatic disease develop, such as<br />anorexia, jaundice, dark urine, pruritus, or tender abdomen.<br />Pseudomembranous colitis has been reported with nearly all antibacterial agents,<br />including macrolides, and may range in severity from mild to life-threatening.<br />Clostridium difficile- associated diarrhoea (CDAD) has been reported with use of<br />nearly all antibacterial agents including clarithromycin, and may range in severity<br />from mild diarrhoea to fatal colitis. Treatment with antibacterial agents alters the<br />normal flora of the colon, which may lead to overgrowth of C. difficile. CDAD<br />must be considered in all patients who present with diarrhoea following antibiotic<br />use. Careful medical history is necessary since CDAD has been reported to occur<br />over two months after the administration of antibacterial agents. Therefore,<br />discontinuation of clarithromycin therapy should be considered regardless of the<br />indication. Microbial testing should be performed and adequate treatment<br />initiated. Drugs inhibiting peristalsis should be avoided.<br />There have been post-marketing reports of colchicine toxicity with concomitant<br />use of clarithromycin and colchicine, especially in the elderly, some of which<br />occurred in patients with renal insufficiency. Deaths have been reported in some<br />such patients (see section 4.5). Concomitant administration of clarithromycin and<br />colchicine is contraindicated (see section 4.3).<br />Caution is advised regarding concomitant administration of clarithromycin and<br />triazolobenzodiazepines, such as triazolam, and intravenous or oromucosal<br />midazolam (see section 4.5).</p><p>Cardiovascular Events:<br />Prolonged cardiac repolarisation and QT interval, imparting a risk of developing<br />cardiac arrhythmia and torsades de pointes, have been seen in treatment with<br />macrolides including clarithromycin (see section 4.8). Therefore, as the following<br />situations may lead to an increased risk for ventricular arrhythmias (including<br />torsades de pointes), clarithromycin should be used with caution in the following<br />patients;<br />&bull; Patients with coronary artery disease, severe cardiac insufficiency,<br />conduction disturbances or clinically relevant bradycardia<br />&bull; Patients with electrolyte disturbances such as hypomagnesaemia.<br />Clarithromycin must not be given to patients with hypokalaemia (see<br />section 4.3).<br />&bull; Patients concomitantly taking other medicinal products associated with QT<br />prolongation (see section 4.5).<br />&bull; Concomitant administration of clarithromycin with astemizole, cisapride,<br />pimozide and terfenadine is contraindicated (see section 4.3).<br />&bull; Clarithromycin must not be used in patients with congenital or documented<br />acquired QT prolongation or history of ventricular arrhythmia (see section<br />4.3).<br />Epidemiological studies investigating the risk of adverse cardiovascular outcomes<br />with macrolides have shown variable results. Some observational studies have&nbsp;</p><p>identified a rare short-term risk of arrhythmia, myocardial infarction and<br />cardiovascular mortality associated with macrolides including clarithromycin.<br />Consideration of these findings should be balanced with treatment benefits when<br />prescribing clarithromycin.<br />Pneumonia: In view of the emerging resistance of Streptococcus pneumoniae to<br />macrolides, it is important that sensitivity testing be performed when prescribing<br />clarithromycin for community-acquired pneumonia. In hospital-acquired<br />pneumonia, clarithromycin should be used in combination with additional<br />appropriate antibiotics.<br />Skin and soft tissue infections of mild to moderate severity: These infections are<br />most often caused by Staphylococcus aureus and Streptococcus pyogenes, both of<br />which may be resistant to macrolides. Therefore, it is important that sensitivity<br />testing be performed. In cases where beta&ndash;lactam antibiotics cannot be used (e.g.<br />allergy), other antibiotics, such as clindamycin, may be the drug of first choice.<br />Currently, macrolides are only considered to play a role in some skin and soft<br />tissue infections, such as those caused by Corynebacterium minutissimum , acne<br />vulgaris, and erysipelas and in situations where penicillin treatment cannot be<br />used.<br />In the event of severe acute hypersensitivity reactions, such as anaphylaxis, severe<br />cutaneous adverse reactions (SCAR) (e.g. Acute generalised exanthematous<br />pustulosis (AGEP), Stevens-Johnson Syndrome, toxic epidermal necrolysis and<br />drug rash with eosinophilia and systemic symptoms (DRESS)), clarithromycin<br />therapy should be discontinued immediately and appropriate treatment should be<br />urgently initiated.<br />Clarithromycin should be used with caution when administered concurrently with<br />medications that induce the cytochrome CYP3A4 enzyme (see section 4.5).</p><p>HMG-CoA Reductase Inhibitors (statins): Concomitant use of clarithromycin with<br />lovastatin or simvastatin is contraindicated (see section 4.3). Caution should be<br />exercised when prescribing clarithromycin with other statins. Rhabdomyolysis has<br />been reported in patients taking clarithromycin and statins. Patients should be<br />monitored for signs and symptoms of myopathy.<br />In situations where the concomitant use of clarithromycin with statins cannot be<br />avoided, it is recommended to prescribe the lowest registered dose of the statin.<br />Use of a statin that is not dependent on CYP3A metabolism (e.g. fluvastatin) can<br />be considered (see 4.5).<br />Oral hypoglycaemic agents/Insulin: The concomitant use of clarithromycin and<br />oral hypoglycaemic agents (such as sulphonylurias) and/or insulin can result in<br />significant hypoglycaemia. Careful monitoring of glucose is recommended (see<br />section 4.5).</p><p>Oral anticoagulants: There is a risk of serious haemorrhage and significant<br />elevations in International Normalized Ratio (INR) and prothrombin time when<br />clarithromycin is co-administered with warfarin (see section 4.5). INR and<br />prothrombin times should be frequently monitored while patients are receiving<br />clarithromycin and oral anticoagulants concurrently.<br />Long-term use may, as with other antibiotics, result in colonisation with increased<br />numbers of non-susceptible bacteria and fungi. If superinfections occur,<br />appropriate therapy should be instituted.<br />Attention should also be paid to the possibility of cross resistance between<br />clarithromycin and other macrolide drugs, as well as lincomycin and clindamycin.<br />Excipients<br />Patients with rare hereditary problems of fructose intolerance, glucose-galactose<br />malabsorption or sucrase-isomaltase insufficiency should not take Klacid Granules<br />for Oral Suspension 125mg/5ml or Klacid Granules for Oral Suspension<br />250mg/5ml. When prescribing to diabetic patients, the sucrose content should be<br />taken into account.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The use of the following drugs is strictly contraindicated due to the potential<br />for severe drug interaction effects:<br />Cisapride, pimozide, astemizole and terfenadine:<br />Elevated cisapride levels have been reported in patients receiving clarithromycin<br />and cisapride concomitantly. This may result in QT prolongation and cardiac<br />arrhythmias including ventricular tachycardia, ventricular fibrillation and torsades<br />de pointes. Similar effects have been observed in patients taking clarithromycin<br />and pimozide concomitantly (see section 4.3).<br />Macrolides have been reported to alter the metabolism of terfenadine resulting in<br />increased levels of terfenadine which has occasionally been associated with<br />cardiac arrhythmias, such as QT prolongation, ventricular tachycardia, ventricular<br />fibrillation and torsades de pointes (see section 4.3). In one study in 14 healthy<br />volunteers, the concomitant administration of clarithromycin and terfenadine<br />resulted in 2- to 3-fold increase in the serum level of the acid metabolite of<br />terfenadine and in prolongation of the QT interval which did not lead to any<br />clinically detectable effect. Similar effects have been observed with concomitant<br />administration of astemizole and other macrolides.</p><p>Ergot alkaloids:<br />Post-marketing reports indicate that co-administration of clarithromycin with<br />ergotamine or dihydroergotamine has been associated with acute ergot toxicity<br />characterized by vasospasm, and ischaemia of the extremities and other tissues</p><p>including the central nervous system. Concomitant administration of<br />clarithromycin and ergot alkaloids is contraindicated (see section 4.3).<br />Oral Midazolam<br />When midazolam was co-administered with clarithromycin tablets (500 mg twice<br />daily), midazolam AUC was increased 7-fold after oral administration of<br />midazolam. Concomitant administration of oral midazolam and clarithromycin is<br />contraindicated(see section 4.3).<br />HMG-CoA Reductase Inhibitors (statins)<br />Concomitant use of clarithromycin with lovastatin or simvastatin is<br />contraindicated (see 4.3) as these statins are extensively metabolized by CYP3A4<br />and concomitant treatment with clarithromycin increases their plasma<br />concentration, which increases the risk of myopathy, including rhabdomyolysis.<br />Reports of rhabdomyolysis have been received for patients taking clarithromycin<br />concomitantly with these statins. If treatment with clarithromycin cannot be<br />avoided, therapy with lovastatin or simvastatin must be suspended during the<br />course of treatment.<br />Caution should be exercised when prescribing clarithromycin with statins. In<br />situations where the concomitant use of clarithromycin with statins cannot be<br />avoided, it is recommended to prescribe the lowest registered dose of the statin.<br />Use of a statin that is not dependent on CYP3A metabolism (e.g.fluvastatin) can<br />be considered. Patients should be monitored for signs and symptoms of myopathy.</p><p>Effects of Other Medicinal Products on Clarithromycin<br />Drugs that are inducers of CYP3A (e.g. rifampicin, phenytoin, carbamazepine,<br />phenobarbital, St John&rsquo;s wort) may induce the metabolism of clarithromycin. This<br />may result in sub-therapeutic levels of clarithromycin leading to reduced efficacy.<br />Furthermore, it might be necessary to monitor the plasma levels of the CYP3A<br />inducer, which could be increased owing to the inhibition of CYP3A by<br />clarithromycin (see also the relevant product information for the CYP3A4 inducer<br />administered). Concomitant administration of rifabutin and clarithromycin resulted<br />in an increase in rifabutin, and decrease in clarithromycin serum levels together<br />with an increased risk of uveitis.<br />The following drugs are known or suspected to affect circulating concentrations of<br />clarithromycin; clarithromycin dosage adjustment or consideration of alternative<br />treatments may be required.<br />Efavirenz, nevirapine, rifampicin, rifabutin and rifapentine<br />Strong inducers of the cytochrome P450 metabolism system such as efavirenz,<br />nevirapine, rifampicin, rifabutin, and rifapentine may accelerate the metabolism of<br />clarithromycin and thus lower the plasma levels of clarithromycin, while<br />increasing those of 14-OH-clarithromycin, a metabolite that is also<br />microbiologically active. Since the microbiological activities of clarithromycin<br />and 14-OH-clarithromycin are different for different bacteria, the intended&nbsp;</p><p>therapeutic effect could be impaired during concomitant administration of<br />clarithromycin and enzyme inducers.<br />Etravirine<br />Clarithromycin exposure was decreased by etravirine; however, concentrations of<br />the active metabolite, 14-OH-clarithromycin, were increased. Because 14-OHclarithromycin<br />has reduced activity against Mycobacterium avium complex<br />(MAC), overall activity against this pathogen may be altered; therefore<br />alternatives to clarithromycin should be considered for the treatment of MAC.<br />Fluconazole<br />Concomitant administration of fluconazole 200 mg daily and clarithromycin 500<br />mg twice daily to 21 healthy volunteers led to increases in the mean steady-state<br />minimum clarithromycin concentration (Cmin) and area under the curve (AUC) of<br />33% and 18% respectively. Steady state concentrations of the active metabolite<br />14-OH-clarithromycin were not significantly affected by concomitant<br />administration of fluconazole. No clarithromycin dose adjustment is necessary.</p><p>Ritonavir<br />A pharmacokinetic study demonstrated that the concomitant administration of<br />ritonavir 200 mg every eight hours and clarithromycin 500 mg every 12 hours<br />resulted in a marked inhibition of the metabolism of clarithromycin. The<br />clarithromycin Cmax increased by 31%, Cmin increased 182% and AUC<br />increased by 77% with concomitant administration of ritonavir. An essentially<br />complete inhibition of the formation of 14-OH-clarithromycin was noted. Because<br />of the large therapeutic window for clarithromycin, no dosage reduction should be<br />necessary in patients with normal renal function. However, for patients with renal<br />impairment, the following dosage adjustments should be considered: For patients<br />with CLCR 30 to 60 mL/min the dose of clarithromycin should be reduced by 50%.<br />For patients with CLCR &lt;30 mL/min the dose of clarithromycin should be<br />decreased by 75%. Doses of clarithromycin greater than 1 g/day should not be coadministered<br />with ritonavir.</p><p>Similar dose adjustments should be considered in patients with reduced renal<br />function when ritonavir is used as a pharmacokinetic enhancer with other HIV<br />protease inhibitors including atazanavir and saquinavir (see section below, Bidirectional<br />drug interactions).</p><p>Effect of Clarithromycin on Other Medicinal Products<br />CYP3A-based interactions<br />Co-administration of clarithromycin, known to inhibit CYP3A, and a drug<br />primarily metabolised by CYP3A may be associated with elevations in drug<br />concentrations that could increase or prolong both therapeutic and adverse effects<br />of the concomitant drug. Clarithromycin should be used with caution in patients<br />receiving treatment with other drugs known to be CYP3A enzyme substrates,</p><p>especially if the CYP3A substrate has a narrow safety margin (e.g.<br />carbamazepine) and/or the substrate is extensively metabolised by this enzyme.<br />Dosage adjustments may be considered, and when possible, serum concentrations<br />of drugs primarily metabolised by CYP3A should be monitored closely in patients<br />concurrently receiving clarithromycin.<br />The following drugs or drug classes are known or suspected to be metabolised by<br />the same CYP3A isozyme: alprazolam, astemizole, carbamazepine, cilostazol,<br />cisapride, ciclosporin, disopyramide, ergot alkaloids, lovastatin,<br />methylprednisolone, midazolam, omeprazole, oral anticoagulants (e.g. warfarin,<br />see 4.4), atypical antipsychotics (e.g. quetiapine), pimozide, quinidine, rifabutin,<br />sildenafil, simvastatin, sirolimus, tacrolimus, terfenadine, triazolam and<br />vinblastine but this list is not exhaustive. Drugs interacting by similar mechanisms<br />through other isozymes within the cytochrome P450 system include phenytoin,<br />theophylline and valproate.</p><p>Antiarrhythmics<br />There have been post-marketed reports of torsades de pointes occurring with the<br />concurrent use of clarithromycin and quinidine or disopyramide.<br />Electrocardiograms should be monitored for QT prolongation during coadministration<br />of clarithromycin with these drugs. Serum levels of quinidine and<br />disopyramide should be monitored during clarithromycin therapy.<br />There have been post marketing reports of hypoglycemia with the concomitant<br />administration of clarithromycin and disopyramide. Therefore blood glucose<br />levels should be monitored during concomitant administration of clarithromycin<br />and disopyramide.<br />Oral hypoglycemic agents/Insulin<br />With certain hypoglycemic drugs such as nateglinide, and repaglinide, inhibition<br />of CYP3A enzyme by clarithromycin may be involved and could cause<br />hypolgycemia when used concomitantly. Careful monitoring of glucose is<br />recommended.</p><p>Omeprazole<br />Clarithromycin (500 mg every 8 hours) was given in combination with omeprazole<br />(40 mg daily) to healthy adult subjects. The steady-state plasma concentrations of<br />omeprazole were increased (Cmax, AUC0-24, and t1/2 increased by 30%, 89%, and<br />34%, respectively), by the concomitant administration of clarithromycin. The<br />mean 24-hour gastric pH value was 5.2 when omeprazole was administered alone<br />and 5.7 when omeprazole was co-administered with clarithromycin.<br />Sildenafil, tadalafil and vardenafil<br />Each of these phosphodiesterase inhibitors is metabolised, at least in part, by<br />CYP3A, and CYP3A may be inhibited by concomitantly administered<br />clarithromycin. Co-administration of clarithromycin with sildenafil, tadalafil or<br />vardenafil would likely result in increased phosphodiesterase inhibitor exposure.</p><p>Reduction of sildenafil, tadalafil and vardenafil dosages should be considered<br />when these drugs are co-administered with clarithromycin.<br />Theophylline, carbamazepine<br />Results of clinical studies indicate that there was a modest but statistically<br />significant (p&le; 0.05) increase of circulating theophylline or carbamazepine levels<br />when either of these drugs were administered concomitantly with clarithromycin.<br />Dose reduction may need to be considered.<br />Tolterodine<br />The primary route of metabolism for tolterodine is via the 2D6 isoform of<br />cytochrome P450 (CYP2D6). However, in a subset of the population devoid of<br />CYP2D6, the identified pathway of metabolism is via CYP3A. In this population<br />subset, inhibition of CYP3A results in significantly higher serum concentrations of<br />tolterodine. A reduction in tolterodine dosage may be necessary in the presence of<br />CYP3A inhibitors, such as clarithromycin in the CYP2D6 poor metaboliser<br />population.</p><p>Triazolobenzodiazepines (e.g., alprazolam, midazolam, triazolam)<br />When midazolam was co-administered with clarithromycin tablets (500 mg twice<br />daily), midazolam AUC was increased 2.7-fold after intravenous administration of<br />midazolam. If intravenous midazolam is co-administered with clarithromycin, the<br />patient must be closely monitored to allow dose adjustment. Drug delivery of<br />midazolam via oromucosal route, which could bypass pre-systemic elimination of<br />the drug, will likely result in a similar interaction to that observed after<br />intravenous midazolam rather than oral administration. The same precautions<br />should also apply to other benzodiazepines that are metabolised by CYP3A,<br />including triazolam and alprazolam. For benzodiazepines which are not dependent<br />on CYP3A for their elimination (temazepam, nitrazepam, lorazepam), a clinically<br />important interaction with clarithromycin is unlikely.<br />There have been post-marketing reports of drug interactions and central nervous<br />system (CNS) effects (e.g., somnolence and confusion) with the concomitant use<br />of clarithromycin and triazolam. Monitoring the patient for increased CNS<br />pharmacological effects is suggested.</p><p>Other drug interactions<br />Colchicine<br />Colchicine is a substrate for both CYP3A and the efflux transporter, Pglycoprotein<br />(Pgp). Clarithromycin and other macrolides are known to inhibit<br />CYP3A and Pgp. When clarithromycin and colchicine are administered together,<br />inhibition of Pgp and/or CYP3A by clarithromycin may lead to increased exposure<br />to colchicine (see section 4.3 and 4.4).</p><p>Digoxin</p><p>Digoxin is thought to be a substrate for the efflux transporter, P-glycoprotein<br />(Pgp). Clarithromycin is known to inhibit Pgp. When clarithromycin and digoxin<br />are administered together, inhibition of Pgp by clarithromycin may lead to<br />increased exposure to digoxin. Elevated digoxin serum concentrations in patients<br />receiving clarithromycin and digoxin concomitantly have also been reported in<br />post marketing surveillance. Some patients have shown clinical signs consistent<br />with digoxin toxicity, including potentially fatal arrhythmias. Serum digoxin<br />concentrations should be carefully monitored while patients are receiving digoxin<br />and clarithromycin simultaneously.</p><p>Zidovudine<br />Simultaneous oral administration of clarithromycin tablets and zidovudine to HIVinfected<br />adult patients may result in decreased steady-state zidovudine<br />concentrations. Because clarithromycin appears to interfere with the absorption of<br />simultaneously administered oral zidovudine, this interaction can be largely<br />avoided by staggering the doses of clarithromycin and zidovudine to allow for a 4-<br />hour interval between each medication. This interaction does not appear to occur<br />in paediatric HIV-infected patients taking clarithromycin suspension with<br />zidovudine or dideoxyinosine. This interaction is unlikely when clarithromycin is<br />administered via intravenous infusion.<br />Phenytoin and Valproate<br />There have been spontaneous or published reports of interactions of CYP3A<br />inhibitors, including clarithromycin with drugs not thought to be metabolised by<br />CYP3A (e.g. phenytoin and valproate). Serum level determinations are<br />recommended for these drugs when administered concomitantly with<br />clarithromycin. Increased serum levels have been reported.</p><p>&nbsp;</p><p>Bi-directional drug interactions<br />Atazanavir<br />Both clarithromycin and atazanavir are substrates and inhibitors of CYP3A, and<br />there is evidence of a bi-directional drug interaction. Co-administration of<br />clarithromycin (500 mg twice daily) with atazanavir (400 mg once daily) resulted<br />in a 2-fold increase in exposure to clarithromycin and a 70% decrease in exposure<br />to 14-OH-clarithromycin, with a 28% increase in the AUC of atazanavir. Because<br />of the large therapeutic window for clarithromycin, no dosage reduction should be<br />necessary in patients with normal renal function. For patients with moderate renal<br />function (creatinine clearance 30 to 60 mL/min), the dose of clarithromycin should<br />be decreased by 50%. For patients with creatinine clearance &lt;30 mL/min, the dose<br />of clarithromycin should be decreased by 75% using an appropriate clarithromycin<br />formulation. Doses of clarithromycin greater than 1000 mg per day should not be<br />co-administered with protease inhibitors.<br />Calcium Channel Blockers<br />Caution is advised regarding the concomitant administration of clarithromycin and<br />calcium channel blockers metabolized by CYP3A4 (e.g. verapamil, amlodipine,<br />diltiazem) due to the risk of hypotension. Plasma concentrations of clarithromycin</p><p>as well as calcium channel blockers may increase due to the interaction.<br />Hypotension, bradyarrhythmias and lactic acidosis have been observed in patients<br />taking clarithromycin and verapamil concomitantly.<br />Itraconazole<br />Both clarithromycin and itraconazole are substrates and inhibitors of CYP3A,<br />leading to a bidirectional drug interaction. Clarithromycin may increase the<br />plasma levels of itraconazole, while itraconazole may increase the plasma levels of<br />clarithromycin. Patients taking itraconazole and clarithromycin concomitantly<br />should be monitored closely for signs or symptoms of increased or prolonged<br />pharmacologic effect.<br />Saquinavir<br />Both clarithromycin and saquinavir are substrates and inhibitors of CYP3A, and<br />there is evidence of a bi-directional drug interaction. Concomitant administration<br />of clarithromycin (500 mg twice daily) and saquinavir (soft gelatin capsules,<br />1200 mg three times daily) to 12 healthy volunteers resulted in steady-state AUC<br />and Cmax values of saquinavir which were 177% and 187% higher than those seen<br />with saquinavir alone. Clarithromycin AUC and Cmax values were approximately<br />40% higher than those seen with clarithromycin alone. No dose adjustment is<br />required when the two drugs are co-administered for a limited time at the<br />doses/formulations studied. Observations from drug interaction studies using the<br />soft gelatin capsule formulation may not be representative of the effects seen using<br />the saquinavir hard gelatin capsule. Observations from drug interaction studies<br />performed with saquinavir alone may not be representative of the effects seen with<br />saquinavir/ritonavir therapy. When saquinavir is co-administered with ritonavir,<br />consideration should be given to the potential effects of ritonavir on<br />clarithromycin (see section 4.5: Ritonavir).<br />Patients taking oral contraceptives should be warned that if diarrhoea, vomiting or<br />breakthrough bleeding occur there is a possibility of contraceptive failure.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pregnancy<br />The safety of clarithromycin for use during pregnancy has not been established.<br />Based on variable results obtained from studies in mice, rats, rabbits and monkeys,<br />the possibility of adverse effects on embryofoetal development cannot be<br />excluded. Therefore, use during pregnancy is not advised without carefully<br />weighing the benefits against risk.<br />Breast-feeding<br />The safety of clarithromycin for using during breast-feeding of infants has not<br />been established. Clarithromycin is excreted into human breast milk.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>There are no data on the effect of clarithromycin on the ability to drive or use<br />machines. The potential for dizziness, vertigo, confusion and disorientation,<br />which may occur with the medication, should be taken into account before patients<br />drive or use machines.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>a. Summary of the safety profile<br />The most frequent and common adverse reactions related to clarithromycin<br />therapy for both adult and paediatric populations are abdominal pain, diarrhoea,<br />nausea, vomiting and taste perversion. These adverse reactions are usually mild in<br />intensity and are consistent with the known safety profile of macrolide antibiotics<br />(see section b of section 4.8).<br />There was no significant difference in the incidence of these gastrointestinal<br />adverse reactions during clinical trials between the patient population with or<br />without pre-existing mycobacterial infections.</p><p>b. Tabulated summary of adverse reactions<br />The following table displays adverse reactions reported in clinical trials and from<br />post-marketing experience with clarithromycin immediate-release tablets,<br />Granules for Oral Suspension, powder for solution for injection, extended-release<br />tablets and modified-release tablets.<br />The reactions considered at least possibly related to clarithromycin are displayed<br />by system organ class and frequency using the following convention: very<br />common (&ge;1/10), common (&ge; 1/100 to &lt; 1/10), uncommon (&ge;1/1,000 to &lt; 1/100)<br />and not known (adverse reactions from post-marketing experience; cannot be<br />estimated from the available data). Within each frequency grouping, adverse<br />reactions are presented in order of decreasing seriousness when the seriousness<br />could be assessed.</p><table border="1" cellspacing="1" cellpadding="1" style="width:616px"><tbody><tr><td style="text-align:center">System Organ<br />Class</td><td style="text-align:center; width:125px">Very common<br />&ge;1/10</td><td style="text-align:center; width:110px">Common<br />&ge; 1/100 to &lt;<br />1/10</td><td style="text-align:center; width:144px">Uncommon<br />&ge;1/1,000 to &lt; 1/100</td><td style="text-align:center; width:145px">Not Known*<br />(cannot be estimated from<br />the available data)</td></tr><tr><td style="text-align:center">Infections and<br />infestations</td><td style="text-align:center; width:125px">&nbsp;</td><td style="text-align:center; width:110px">&nbsp;</td><td style="text-align:center; width:144px">Cellulitis1, candidiasis,<br />gastroenteritis2,<br />infection3, vaginal<br />infection</td><td style="text-align:center; width:145px">Pseudomembranous<br />colitis, erysipelas,</td></tr><tr><td style="text-align:center">Blood and<br />lymphatic<br />system</td><td style="text-align:center; width:125px">&nbsp;</td><td style="text-align:center; width:110px">&nbsp;</td><td style="text-align:center; width:144px">Leukopenia,<br />neutropenia4,<br />thrombocythaemia3,<br />eosinophilia4</td><td style="text-align:center; width:145px">Agranulocytosis,<br />thrombocytopenia</td></tr><tr><td style="text-align:center">Immune system&nbsp;disorders</td><td style="text-align:center; width:125px">&nbsp;</td><td style="text-align:center; width:110px">&nbsp;</td><td style="text-align:center; width:144px">Anaphylactoid reaction1,&nbsp;hypersensitivity</td><td style="text-align:center; width:145px">Anaphylactic reaction.&nbsp;angioedema</td></tr><tr><td style="text-align:center">Metabolism and<br />nutrition<br />disorders</td><td style="text-align:center; width:125px">&nbsp;</td><td style="text-align:center; width:110px">&nbsp;</td><td style="text-align:center; width:144px">Anorexia, decreased<br />appetite</td><td style="text-align:center; width:145px">&nbsp;</td></tr><tr><td style="text-align:center">Psychiatric<br />disorders</td><td style="text-align:center; width:125px">&nbsp;</td><td style="text-align:center; width:110px">Insomnia</td><td style="text-align:center; width:144px">Anxiety, nervousness3,</td><td style="text-align:center; width:145px">Psychotic disorder,<br />confusional state5,<br />depersonalisation,<br />depression, disorientation,<br />hallucination, abnormal<br />dreams, mania</td></tr><tr><td style="text-align:center">Nervous system<br />disorders</td><td style="text-align:center; width:125px">&nbsp;</td><td style="text-align:center; width:110px">Dysgeusia,<br />headache</td><td style="text-align:center; width:144px">Loss of consciousness1,<br />dyskinesia1, dizziness,<br />somnolence5, tremor</td><td style="text-align:center; width:145px">Convulsion, ageusia,<br />parosmia, anosmia,<br />paraesthesia</td></tr><tr><td style="text-align:center">Ear and<br />labyrinth<br />disorders</td><td style="text-align:center; width:125px">&nbsp;</td><td style="text-align:center; width:110px">&nbsp;</td><td style="text-align:center; width:144px">Vertigo, hearing<br />impaired, tinnitus</td><td style="text-align:center; width:145px">Deafness</td></tr><tr><td style="text-align:center">Cardiac<br />disorders</td><td style="text-align:center; width:125px">&nbsp;</td><td style="text-align:center; width:110px">&nbsp;</td><td style="text-align:center; width:144px">Cardiac arrest1, atrial<br />fibrillation1,<br />electrocardiogram QT<br />prolonged,<br />extrasystoles1,<br />palpitations</td><td style="text-align:center; width:145px">Torsades de pointes,<br />ventricular tachycardia,<br />ventricular fibrillation</td></tr><tr><td style="text-align:center">Vascular<br />disorders</td><td style="text-align:center; width:125px">&nbsp;</td><td style="text-align:center; width:110px">Vasodilation1</td><td style="text-align:center; width:144px">&nbsp;</td><td style="text-align:center; width:145px">Haemorrhage</td></tr><tr><td style="text-align:center">Respiratory,<br />thoracic and<br />mediastinal<br />disorder</td><td style="text-align:center; width:125px">&nbsp;</td><td style="text-align:center; width:110px">&nbsp;</td><td style="text-align:center; width:144px">Asthma1, epistaxis2,<br />pulmonary embolism1</td><td style="text-align:center; width:145px">&nbsp;</td></tr><tr><td style="text-align:center">Gastrointestinal<br />disorders</td><td style="text-align:center; width:125px">&nbsp;</td><td style="text-align:center; width:110px">Diarrhoea,<br />vomiting,<br />dyspepsia,<br />nausea,<br />abdominal pain</td><td style="text-align:center; width:144px">Oesophagitis1,<br />gastrooesophageal reflux<br />disease2, gastritis,<br />proctalgia2, stomatitis,<br />glossitis, abdominal<br />distension4, constipation,<br />dry mouth, eructation,<br />flatulence,</td><td style="text-align:center; width:145px">Pancreatitis acute, tongue<br />discolouration, tooth<br />discolouration</td></tr><tr><td style="text-align:center">Hepatobiliary<br />disorders</td><td style="text-align:center; width:125px">&nbsp;</td><td style="text-align:center; width:110px">Liver function<br />test abnormal</td><td style="text-align:center; width:144px">Cholestasis4, hepatitis4,<br />alanine aminotransferase<br />increased, aspartate<br />aminotransferase<br />increased, gammaglutamyltransferase<br />increased4</td><td style="text-align:center; width:145px">Hepatic failure, jaundice<br />hepatocellular</td></tr><tr><td style="text-align:center">Skin and<br />subcutaneous<br />tissue disorders</td><td style="text-align:center; width:125px">&nbsp;</td><td style="text-align:center; width:110px">Rash,<br />hyperhidrosis</td><td style="text-align:center; width:144px">Dermatitis bullous1,<br />pruritus, urticaria, rash<br />maculo-papular3</td><td style="text-align:center; width:145px">Severe cutaneous adverse<br />reactions (SCAR) (e.g.<br />Acute generalised<br />exanthematous pustulosis<br />(AGEP),Stevens-Johnson<br />syndrome, toxic epidermal<br />necrolysis, drug rash with<br />eosinophilia and systemic<br />symptoms (DRESS)), acne</td></tr><tr><td style="text-align:center">Musculoskeleta<br />l and<br />connective<br />tissue disorders</td><td style="text-align:center; width:125px">&nbsp;</td><td style="text-align:center; width:110px">&nbsp;</td><td style="text-align:center; width:144px">Muscle spasms3,<br />musculoskeletal<br />stiffness1, myalgia2</td><td style="text-align:center; width:145px">Rhabdomyolysis2,,<br />myopathy</td></tr><tr><td style="text-align:center">Renal and<br />urinary<br />disorders</td><td style="text-align:center; width:125px">&nbsp;</td><td style="text-align:center; width:110px">&nbsp;</td><td style="text-align:center; width:144px">Blood creatinine<br />increased1, blood urea<br />increased1</td><td style="text-align:center; width:145px">Renal failure, nephritis<br />interstitial</td></tr><tr><td style="text-align:center">General<br />disorders and<br />administration<br />site conditions</td><td style="text-align:center; width:125px">Injection site<br />phlebitis1</td><td style="text-align:center; width:110px">Injection site<br />pain1, injection<br />site<br />inflammation1</td><td style="text-align:center; width:144px">Malaise4, pyrexia3,<br />asthenia, chest pain4,<br />chills4, fatigue4</td><td style="text-align:center; width:145px">&nbsp;</td></tr><tr><td style="text-align:center">Investigations</td><td style="text-align:center; width:125px">&nbsp;</td><td style="text-align:center; width:110px">&nbsp;</td><td style="text-align:center; width:144px">Albumin globulin ratio<br />abnormal1, blood<br />alkaline phosphatase<br />increased4,<br />blood lactate<br />dehydrogenase<br />increased4</td><td style="text-align:center; width:145px">International normalised<br />ratio increased,<br />prothrombin time<br />prolonged, urine colour<br />abnormal</td></tr></tbody></table><p>1 ADRs reported only for the Powder for Concentrate for Solution for Infusion<br />formulation<br />2ADRs reported only for the Extended-Release Tablets formulation<br />3 ADRs reported only for the Granules for Oral Suspension formulation<br />4 ADRs reported only for the Immediate-Release Tablets formulation<br />5, 6 See section c)</p><p>* Because these reactions are reported voluntarily from a population of uncertain<br />size, it is not always possible to reliably estimate their frequency or establish a<br />causal relationship to drug exposure. Patient exposure is estimated to be greater<br />than 1 billion patient treatment days for clarithromycin.</p><p>c. Description of selected adverse reactions<br />Injection site phlebitis, injection site pain, and injection site inflammation are<br />specific to the clarithromycin intravenous formulation.<br />In some of the reports of rhabdomyolysis, clarithromycin was administered<br />concomitantly with statins, fibrates, colchicine or allopurinol (see section 4.3 and<br />4.4).<br />There have been post-marketing reports of drug interactions and central nervous<br />system (CNS) effects (e.g. somnolence and confusion) with the concomitant use of<br />clarithromycin and triazolam. Monitoring the patient for increased CNS<br />pharmacological effects is suggested (see section 4.5).<br />There have been rare reports of clarithromycin ER tablets in the stool, many of<br />which have occurred in patients with anatomic (including ileostomy or colostomy)<br />or functional gastrointestinal disorders with shortened GI transit times. In several<br />reports, tablet residues have occurred in the context of diarrhoea. It is<br />recommended that patients who experience tablet residue in the stool and no<br />improvement in their condition should be switched to a different clarithromycin<br />formulation (e.g. suspension) or another antibiotic.<br />Special population: Adverse Reactions in Immunocompromised Patients (see<br />section e).</p><p>d. Paediatric populations<br />Clinical trials have been conducted using clarithromycin Granules for Oral<br />Suspension in children 6 months to 12 years of age. Therefore, children under 12<br />years of age should use clarithromycin Granules for Oral Suspension.<br />Frequency, type and severity of adverse reactions in children are expected to be<br />the same as in adults.</p><p>e. Other special populations<br />Immunocompromised patients<br />In AIDS and other immunocompromised patients treated with the higher doses of<br />clarithromycin over long periods of time for mycobacterial infections, it was often<br />difficult to distinguish adverse events possibly associated with clarithromycin<br />administration from underlying signs of Human Immunodeficiency Virus (HIV)<br />disease or intercurrent illness.<br />In adult patients, the most frequently reported adverse reactions by patients treated<br />with total daily doses of 1000 mg and 2000mg of clarithromycin were: nausea,<br />vomiting, taste perversion, abdominal pain, diarrhoea, rash, flatulence, headache,<br />constipation, hearing disturbance, Serum Glutamic Oxaloacetic Transaminase<br />(SGOT) and Serum Glutamic Pyruvate Transaminase (SGPT) elevations.<br />Additional low-frequency events included dyspnoea, insomnia and dry mouth.<br />The incidences were comparable for patients treated with 1000mg and 2000mg,<br />but were generally about 3 to 4 times as frequent for those patients who received<br />total daily doses of 4000mg of clarithromycin.<br />In these immunocompromised patients, evaluations of laboratory values were<br />made by analysing those values outside the seriously abnormal level (i.e. the<br />extreme high or low limit) for the specified test. On the basis of these criteria,<br />about 2% to 3% of those patients who received 1000mg or 2000mg of<br />clarithromycin daily had seriously abnormal elevated levels of SGOT and SGPT,<br />and abnormally low white blood cell and platelet counts. A lower percentage of<br />patients in these two dosage groups also had elevated Blood Urea Nitrogen levels.<br />Slightly higher incidences of abnormal values were noted for patients who<br />received 4000mg daily for all parameters except White Blood Cell.</p><p><strong>To report any side effect(s):</strong></p><p>-National Pharmacovigilance Center (NPC)</p><p><strong>o </strong>Fax: +966-11-205-7662</p><p><strong>o </strong>SFDA Call Center: 19999</p><p>o E-mail: npc.drug@sfda.gov.sa</p><p>o Website: https://ade.sfda.gov.sa</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Reports indicate that the ingestion of large amounts of clarithromycin can be<br />expected to produce gastro-intestinal symptoms. One patient who had a history of<br />bipolar disorder ingested 8 grams of clarithromycin and showed altered mental<br />status, paranoid behaviour, hypokalaemia and hypoxaemia.<br />Adverse reactions accompanying overdosage should be treated by the prompt<br />elimination of unabsorbed drug and supportive measures. As with other<br />macrolides, clarithromycin serum levels are not expected to be appreciably<br />affected by haemodialysis or peritoneal dialysis.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>ATC Classification:<br />Pharmacotherapeutic group: Antibacterial for systemic use, macrolide<br />ATC-Code: J01FA09<br />Mode of Action:<br />Clarithromycin is an antibiotic belonging to the macrolide antibiotic group. It<br />exerts its anti-bacterial action by selectively binding to the 50s ribosomal sub-unit<br />of susceptible bacteria preventing translocation of activated amino acids. It<br />inhibits the intracellular protein synthesis of susceptible bacteria.<br />The 14-hydroxy metabolite of clarithromycin, a product of parent drug metabolism<br />also has anti-microbial activity. The metabolite is less active than the parent<br />compound for most organisms, including mycobacterium spp. An exception is<br />Haemophilus influenza where the 14-hydroxy metabolite is two-fold more active<br />than the parent compound.<br />Clarithromycin is also bactericidal against several bacterial strains.<br />Clarithromycin is usually active against the following organisms in vitro:-<br />Gram-positive Bacteria: Staphylococcus aureus (methicillin susceptible);<br />Streptococcus pyogenes (Group A beta-haemolytic streptococci); alphahaemolytic<br />streptococci (viridans group); Streptococcus (Diplococcus)<br />pneumoniae; Streptococcus agalactiae; Listeria monocytogenes.<br />Gram-negative Bacteria: Haemophilus influenzae, Haemophilus parainfluenzae,<br />Moraxella (Branhamella) catarrhalis, Neisseria gonorrhoeae; Legionella<br />pneumophila, Bordetella pertussis, Helicobacter pylori; Campylobacter jejuni.<br />Mycoplasma: Mycoplasma pneumoniae; Ureaplasma urealyticum.</p><p>Other Organisms: Chlamydia trachomatis; Mycobacterium avium;<br />Mycobacterium leprae; Chlamydia pneumoniae.<br />Anaerobes: Macrolide-susceptible Bacteroides fragilis; Clostridium perfringens;<br />Peptococcus species; Peptostreptococcus species; Propionibacterium acnes.<br />Clarithromycin also has bactericidal activity against several bacterial strains.<br />These organisms include H. influenzae, Streptococcus pneumoniae, Streptococcus<br />pyogenes, Streptococcus agalactiae, Moraxella (Brahamella) catarrhalis, Neisseria<br />gonorrhoeae, Helicobacter pylori and Campylobacter species.</p><p>Breakpoints<br />The following breakpoints have been established by the European Committee for<br />Antimicrobial Susceptibility Testing (EUCAST).</p><p>&nbsp;</p><table border="1" cellspacing="1" cellpadding="1" style="width:500px"><tbody><tr><td colspan="3" style="text-align:center">Breakpoints (MIC, mg/L)</td></tr><tr><td style="text-align:center">Microorganism</td><td style="text-align:center">Susceptible (&le;)</td><td style="text-align:center">Resistant (&gt;)</td></tr><tr><td style="text-align:center">Staphylococcus spp.</td><td style="text-align:center">1 mg/L</td><td style="text-align:center">2 mg/L</td></tr><tr><td style="text-align:center">Streptococcus A, B, C<br />and G</td><td style="text-align:center">0.25 mg/L</td><td style="text-align:center">0.5 mg/L</td></tr><tr><td style="text-align:center">Streptococcus<br />pneumonia</td><td style="text-align:center">0.25 mg/L</td><td style="text-align:center">0.5 mg/L</td></tr><tr><td style="text-align:center">Viridans group<br />streptococcus</td><td style="text-align:center">IE</td><td style="text-align:center">IE</td></tr><tr><td style="text-align:center">Haemophilus spp.</td><td style="text-align:center">1 mg/L</td><td style="text-align:center">32 mg/L</td></tr><tr><td style="text-align:center">Moraxella<br />catarrhalis</td><td style="text-align:center">0.25 mg/L</td><td style="text-align:center">0.5 mg/L 1</td></tr><tr><td style="text-align:center">Helicobacter pylori</td><td style="text-align:center">0.25 mg/L1</td><td style="text-align:center">0.5 mg/L</td></tr></tbody></table><p>1 The breakpoints are based on epidemiological cut-off values (ECOFFs),<br />which distinguish wild-type isolates from those with reduces<br />susceptibility.<br />&ldquo;IE&quot; indicates that there is insufficient evidence that the species in<br />question is a good target for therapy with the drug.</p><p>&nbsp;</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Clarithromycin is rapidly and well absorbed from the gastro-intestinal tract after<br />oral administration. The microbiologically active 14(R)-hydroxyclarithromycin is<br />formed by first pass metabolism. Clarithromycin, may be given without regard to<br />meals as food does not affect the extent of bioavailability. Food does slightly<br />delay the onset of absorption of clarithromycin and formation of the 14-hydroxy<br />metabolite. Although the pharmacokinetics of clarithromycin are non linear,</p><p>steady state is attained within 2 days of dosing. 14-Hydroxyclarithromycin is the<br />major urinary metabolite and accounts for 10-15% of the dose. Most of the<br />remainder of the dose is eliminated in the faeces, primarily via the bile. 5-10% of<br />the parent drug is recovered from the faeces.<br />Clarithromycin provides tissue concentrations that are several times higher than<br />circulating drug level. Increased levels of clarithromycin have been found in both<br />tonsillar and lung tissue. Clarithromycin penetrates into the middle ear fluid at<br />concentrations greater than in the serum. Clarithromycin is 80% bound to plasma<br />proteins at therapeutic levels.<br />Klacid Granules for Oral Suspension 125mg/5ml does not contain tartrazine or<br />other azo dyes, lactose or gluten.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The acute oral LD50 values for a clarithromycin suspension administered to 3-day<br />old mice were 1290 mg/kg for males and 1230 mg/kg for females. The LD50<br />values in 3-day old rats were 1330 mg/kg for males and 1270 mg/kg for females.<br />For comparison, the LD50 of orally-administered clarithromycin is about 2700<br />mg/kg for adult mice and about 3000 mg/kg for adult rats. These results are<br />consistent with other antibiotics of the penicillin group, cephalosporin group and<br />macrolide group in that the LD50 is generally lower in juvenile animals than in<br />adults.<br />In both mice and rats, body weight was reduced or its increase suppressed and<br />suckling behaviour and spontaneous movements were depressed for the first few<br />days following drug administration. Necropsy of animals that died disclosed darkreddish<br />lungs in mice and about 25% of the rats; rats treated with 2197 mg/kg or<br />more of a clarithromycin suspension were also noted to have a reddish - black<br />substance in the intestines, probably because of bleeding. Deaths of these animals<br />were considered due to debilitation resulting from depressed suckling behaviour or<br />bleeding from the intestines.<br />Pre-weaning rats (5 days old) were administered a clarithromycin suspension<br />formulation for two weeks at doses of 0, 15, 55 and 200 mg/kg/day. Animals from<br />the 200 mg/kg/day group had decreased body-weight gains, decreased mean<br />haemoglobin and haematocrit values, and increased mean relative kidney weights<br />compared to animals from the control group. Treatment-related minimal to mild<br />multifocal vacuolar degeneration of the intrahepatic bile duct epithelium and an<br />increased incidence of nephritic lesions were also observed in animals from this<br />treatment group. The &quot;no-toxic effect&quot; dosage for this study was 55 mg/kg/day.<br />An oral toxicity study was conducted in which immature rats were administered a<br />clarithromycin suspension (granules for suspension) for 6 weeks at daily dosages of<br />0, 15, 50 and 150 mg base/kg/day. No deaths occurred and the only clinical sign<br />observed was excessive salivation for some of the animals at the highest dosage<br />from 1 to 2 hours after administration during the last 3 weeks of treatment. Rats</p><p>from the 150 mg/kg dose group had lower mean body weights during the first three<br />weeks, and were observed to have decreased mean serum albumin values and<br />increased mean relative liver weight compared to the controls. No treatment-related<br />gross or microscopic histopathological changes were found. A dosage of 150<br />mg/kg/day produced slight toxicity in the treated rats and the &quot;no effect dosage&quot; was<br />considered to be 50 mg/kg/day.<br />Juvenile beagle dogs, 3 weeks of age, were treated orally daily for four weeks with<br />0, 30, 100, or 300 mg/kg of clarithromycin, followed by a 4-week recovery period.<br />No deaths occurred and no changed in the general condition of the animals were<br />observed. Necropsy revealed no abnormalities. Upon histological examination,<br />fatty deposition of centrilobular hepatocytes and cell infiltration of portal areas were<br />observed by light microscopy and an increase in hepatocellular fat droplets was<br />noted by electron microscopy in the 300 mg/kg dose group. The toxic dose in<br />juvenile beagle dogs was considered to be greater than 300 mg/kg and the &quot;no effect<br />dose&quot; 100 mg/kg.<br />Fertility, Reproduction and Teratogenicity<br />Fertility and reproduction studies have shown daily dosages of 150-160 mg/kg/day<br />to male and female rats caused no adverse effects on the oestrus cycle, fertility,<br />parturition and number and viability of offspring. Two teratogenicity studies in<br />both Wistar (p.o.) and Sprague-Dawley (p.o. and i.v.) rats, one study in New<br />Zealand white rabbits and one study in cynomolgus monkeys failed to demonstrate<br />any teratogenicity from clarithromycin.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Granule component and coating:<br />Carbopol Carbomers<br />Povidone<br />Hypromellose<br />Castor Oil<br />Other ingredients:<br />Silicon dioxide<br />Sucrose<br />Xanthan gum<br />Flavour - fruit punch<br />Potassium sorbate<br />Citric acid<br />Titanium dioxide<br />Maltodextrin</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>None known.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                The recommended shelf life is 24 months. Once reconstituted, Klacid Granules for
Oral Suspension 125mg/5ml should be used within 14 days.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Do not store above 30&deg;C.<br />After reconstitution you can store at room temperature (15 - 30 &deg;C) for 14 days</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Granules for reconstitution in a HDPE bottle with a PS-measuring spoon. Pack sizes<br />of 60 and 100 ml are available.<br />Not all pack sizes may be marketed.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>100ml bottle: 53ml of water should be added to the granules in the bottle and<br />shaken until all of the particles are suspended. Avoid vigorous and/ or lengthy<br />shaking. Shake prior to each subsequent use to ensure re-suspension. The<br />concentration of clarithromycin in the reconstituted suspension is 125mg per 5ml.</p><p><br />60ml bottle: 31ml of water should be added to the granules in the bottle and shaken<br />until all of the particles are suspended. Avoid vigorous and/ or lengthy shaking.<br />Shake prior to each subsequent use to ensure re-suspension. The concentration of<br />clarithromycin in the reconstituted suspension is 125mg per 5ml.</p><p><br />Administration<br />Several devices can be used to dose and administer Clarithromycin Pediatric<br />Suspension.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Abbott Laboratories Ltd.
Abbott House, Vanwall Business park
Vanwall Road, Maidenhead Berkshire
SL6 4XE, UK
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                June 2020
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>